Citation

Vadivelu N, Schermer E, Kodumudi G, Berger JM. CNS Drugs 2016; 30(7): 637-646.

Affiliation

Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

Copyright

(Copyright © 2016, Adis International)

DOI

10.1007/s40263-016-0357-0

PMID

27290716

Abstract

Opioids are the mainstay for treatment of acute pain and cancer pain, and also have a role in the treatment of chronic non-malignant pain. There has been, however, a growing public health problem stemming from the misuse of opioid analgesics leading to serious consequences. To deter abuse, new formulations of extended-release opioid analgesics and tamper-resistant opioids have recently been developed. The concept of abuse-deterrent extended-release opioids is relatively new and, although abuse may not be completely prevented, the utilization of such abuse-deterrent extended-release opioids could reduce this risk. Extended-release abuse-deterrent opioids have been found to have important clinical applications in cancer, acute pain, and chronic non-malignant pain for analgesia control with decreased incidence of tampering and abuse. In this review, different extended-release formulations of opioids available for clinical applications are presented with descriptions of the formulations, their physical properties, and the clinical studies performed to provide physicians with a better understanding of their uses.

Language: en